Intervention
Acipimox
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownThe Effect of Acipimox on GLP (Glucagon-like Peptide)-1 SecretionNCT02796950 · 2016-06-01
COMPLETEDThe Effect of Pharmacological Antilipolysis on the Metabolic Effects of GhrelinNCT01209416 · 2012-06-01
COMPLETEDEffects of Acipimox on Mitochondrial Function in ObesityNCT01488409 · 2012-05-01
COMPLETEDEffects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 DiabetesNCT01816165 · 2011-06-01
COMPLETEDEvaluating the Effects of a Study Medication on Exercise Function in Type 2 DiabetesNCT01580813 · 2011-06-01
COMPLETEDEffect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During ExerciseNCT01260376 · 2011-04-01
COMPLETEDCross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial FunctionNCT00943059 · 2010-03-01
COMPLETEDAcipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIVNCT00246402 · 2002-09-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED8
Phase mix
NA6
PHASE21
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.